These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33244378)

  • 1. Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19.
    Absalan A; Doroud D; Salehi-Vaziri M; Kaghazian H; Ahmadi N; Zali F; Pouriavali's MH; Mousavi-Nasab SD
    Gastroenterol Hepatol Bed Bench; 2020; 13(4):355-360. PubMed ID: 33244378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2.
    Sharma P; Vijayan V; Pant P; Sharma M; Vikram N; Kaur P; Singh TP; Sharma S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6649-6659. PubMed ID: 32741313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Iminosugars as Antiviral Agents against SARS-CoV-2 Main Protease: Inhibitor Design and Optimization, Molecular Docking, and Molecular Dynamics Studies to Explore Potential Inhibitory Effect of 1-Deoxynojirmycin Series.
    Miglani V; Sharma P; Kumar Narula A
    Curr Comput Aided Drug Des; 2023 Aug; ():. PubMed ID: 37612857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.
    Gupta A; Rani C; Pant P; Vijayan V; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    ACS Omega; 2020 Dec; 5(51):33151-33161. PubMed ID: 33398250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
    Rahman MM; Saha T; Islam KJ; Suman RH; Biswas S; Rahat EU; Hossen MR; Islam R; Hossain MN; Mamun AA; Khan M; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6231-6241. PubMed ID: 32692306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
    Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
    Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.
    Daoud S; Alabed SJ; Dahabiyeh LA
    Acta Pharm; 2021 Jun; 71(2):163-174. PubMed ID: 33151166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsymmetrical aromatic disulfides as SARS-CoV-2 Mpro inhibitors: Molecular docking, molecular dynamics, and ADME scoring investigations.
    Chtita S; Belaidi S; Qais FA; Ouassaf M; AlMogren MM; Al-Zahrani AA; Bakhouch M; Belhassan A; Zaki H; Bouachrine M; Lakhlifi T
    J King Saud Univ Sci; 2022 Oct; 34(7):102226. PubMed ID: 35875823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M
    Abosheasha MA; El-Gowily AH
    Drug Dev Res; 2021 Apr; 82(2):217-229. PubMed ID: 32984987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.